US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ACRES Commercial Realty Corp.

19.16

+0.65003.51%

Post-market: 20.201.04+5.43%19:59 EDT

Volume:30.22K

Turnover:577.62K

Market Cap:142.86M

PE:16.66

High:19.58

Open:18.53

Low:18.45

Close:18.51

Loading ...

Overview Company News Filings

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Acres Commercial Realty Corp reports results for the quarter ended December 31 - Earnings Summary

ACRES Commercial (ACR) Q4 Earnings Surpass Estimates

BRIEF-Acres Commercial Realty Q4 Net Income USD 4.1 Million

ACRES Commercial Realty Q4 Adj $0.48 Beats $0.27 Estimate, Sales $21.43M Miss $21.96M Estimate

ACRES Commercial Realty Corp. reports Q4 EPS 52c vs. 55c a year ago

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2024 AND YEAR ENDED DECEMBER 31, 2024

Acres Commercial Realty Corp expected to post earnings of 27 cents a share - Earnings Preview

Press Release: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2024

ACRES Commercial Realty Corp. (NYSE:ACR) is a favorite amongst institutional investors who own 51%

Simply Wall St.

Acrivon Therapeutics announces FDA granted BDD for ACR-368

Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation

MT Newswires Live

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

XBiotech Pauses Rheumatology program

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Acrux Ltd Raises A$1.34 Mln From Share Purchase Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","market":"US","secType":"STK","nameCN":"ACRES Commercial Realty Corp.","latestPrice":19.16,"timestamp":1745956800000,"preClose":18.51,"halted":0,"volume":30221,"hourTrading":{"tag":"盘后","latestPrice":20.2,"preClose":19.16,"latestTime":"19:59 EDT","volume":741,"amount":14841.06,"timestamp":1745971163699},"delay":0,"floatShares":7105800,"shares":7456150,"eps":1.149999,"marketStatus":"Not Yet Opened","change":0.65,"latestTime":"04-29 16:00:00 EDT","open":18.53,"high":19.58,"low":18.445,"amount":577620.742504,"amplitude":0.061318,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.149999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746000000000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":18.51,"dividendRate":0.043058,"preHourTrading":{"tag":"盘前","latestPrice":18.51,"preClose":18.51,"latestTime":"09:06 EDT","volume":18,"amount":332.63000999999997,"timestamp":1745931967904},"postHourTrading":{"tag":"盘后","latestPrice":20.2,"preClose":19.16,"latestTime":"19:59 EDT","volume":741,"amount":14841.06,"timestamp":1745971163699},"volumeRatio":0.789126,"impliedVol":0.2004,"impliedVolPercentile":0.3092},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACR\",,,,,undefined,":{"symbol":"ACR","floatShares":7105800,"roa":"1.41%","roe":"6.41%","lyrEps":1.191983,"volumeRatio":0.789126,"shares":7456150,"dividePrice":0.825,"high":19.58,"amplitude":0.061318,"preClose":18.51,"low":18.445,"week52Low":12.33,"pbRate":"0.33","psRate":"1.82","week52High":23.81,"institutionHeld":0.1601,"latestPrice":19.16,"eps":1.149999,"divideRate":0.043058,"volume":30221,"delay":0,"ttmEps":1.149999,"open":18.53,"prevYearClose":16.15,"prevWeekClose":18.58,"prevMonthClose":21.67,"prevQuarterClose":21.67,"fiveDayClose":17.53,"twentyDayClose":21.67,"sixtyDayClose":17.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517911392","title":"Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911392","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911392?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:01","pubTimestamp":1741294860,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis  patient cohort in 1H25. Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25. Initiation of ADI-001 Phase 1 clinical trial patient enrollment in systemic lupus erythematosus , systemic sclerosis , idiopathic inflammatory myopathy  and stiff person syndrome  expected in 2Q25; anti-neutrophil cytoplasmic autoantibody  associated vasculitis  patient enrollment expected to be initiated in 2H25. Continuing to advance phase 1 trial of ADI-001 in autoimmune diseases. In November 2024, Adicet announced the dosing of the first patient in the Phase 1 trial evaluating ADI-001 in LN. Enrollment for SLE, SSc, IIM, and SPS patients is expected to commence in the second quarter of 2025, with the initiation of AAV patient enrollment anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-reports-fourth-quarter-210100654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4077","BK4139","BK4231","SITC","LU2065732104.USD","ACET","ACR","BK4230","IIM","BK4110","BK4097","CAR","BK4022","SLE","PRGS"],"gpt_icon":0},{"id":"2517441977","title":"Acres Commercial Realty Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517441977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517441977?lang=en_us&edition=fundamental","pubTime":"2025-03-06 09:56","pubTimestamp":1741226202,"startTime":"0","endTime":"0","summary":"Acres Commercial Realty Corp reports results for the quarter ended December 31 - Earnings SummaryAcres Commercial Realty Corp ACR.N reported quarterly adjusted earnings of 48 cents per share for the q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP01H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR"],"gpt_icon":0},{"id":"2517971277","title":"ACRES Commercial (ACR) Q4 Earnings Surpass Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971277","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971277?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:50","pubTimestamp":1741218602,"startTime":"0","endTime":"0","summary":"ACRES Commercial  came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 118.18%. A quarter ago, it was expected that this commercial real estate investment trust would post earnings of $0.39 per share when it actually produced earnings of $0.24, delivering a surprise of -38.46%.ACRES Commercial , which belongs to the Zacks REIT and Equity Trust industry, posted revenues of $8.6 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 15.73%. This compares to year-ago revenues of $13.36 million. The company has not been able to beat consensus revenue estimates over the last four quarters.ACRES Commercial shares have added about 26.9% since the beginning of the year versus the S&P 500's decline of -1.8%.While ACRES Commercial has outperformed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-acr-q4-earnings-235002132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFCG","ACR"],"gpt_icon":0},{"id":"2517978460","title":"BRIEF-Acres Commercial Realty Q4 Net Income USD 4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978460?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:05","pubTimestamp":1741215936,"startTime":"0","endTime":"0","summary":"BRIEF-Acres Commercial Realty Q4 Net Income USD 4.1 MillionMarch 5 (Reuters) - Acres Commercial Realty Corp ACR.N:ACRES COMMERCIAL REALTY Q4 NET INCOME USD 4.1 MILLIONSource text: ID:nPn9Zd9MgaFurther company coverage: ACR.N ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nPLXEAF388:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR"],"gpt_icon":0},{"id":"2517924900","title":"ACRES Commercial Realty Q4 Adj $0.48 Beats $0.27 Estimate, Sales $21.43M Miss $21.96M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517924900","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517924900?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:35","pubTimestamp":1741210511,"startTime":"0","endTime":"0","summary":"ACRES Commercial Realty (NYSE:ACR) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.27 by 77.78 percent. This is a 12.73 percent decrease over earnings of $0.55 per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44153330/acres-commercial-realty-q4-adj-0-48-beats-0-27-estimate-sales-21-43m-miss-21-96m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ACRES Commercial Realty Q4 Adj $0.48 Beats $0.27 Estimate, Sales $21.43M Miss $21.96M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR"],"gpt_icon":0},{"id":"2517492425","title":"ACRES Commercial Realty Corp. reports Q4 EPS 52c vs. 55c a year ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2517492425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517492425?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:30","pubTimestamp":1741210257,"startTime":"0","endTime":"0","summary":"“The ACRES team continues to proactively manage the investment portfolio. As always, our primary objective is to protect and enhance shareholder va...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acres-commercial-realty-corp-reports-q4-eps-52c-vs-55c-a-year-ago?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acres-commercial-realty-corp-reports-q4-eps-52c-vs-55c-a-year-ago?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACR"],"gpt_icon":0},{"id":"2517692171","title":"ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2024 AND YEAR ENDED DECEMBER 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517692171","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517692171?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:15","pubTimestamp":1741209300,"startTime":"0","endTime":"0","summary":"UNIONDALE, N.Y., March 5, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp.  ,a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter and year ended December31, 2024. ACR's GAAP net income allocable to common shares was $4.1 million or $0.52 per share-diluted, for the quarter ended December31, 2024.\"The ACRES team continues to proactively manage the investment portfolio. As always, our primary objective is to protect and enhance shareholder value,\" said ACRES Commercial Realty Corp. President & CEO Mark Fogel. \"In 2024, we saw a healthy amount of loans payoff and renewed transactional activity in the real estate markets. Heading into 2025, we to intend to grow our loan portfolio by investing with experienced sponsors in high-growth markets nationwide.\". ACR issued a full","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-reports-211500309.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-reports-211500309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4024","YEAR","CORP","FOR","ACR","BK4550","BK4110"],"gpt_icon":0},{"id":"2516583669","title":"Acres Commercial Realty Corp  expected to post earnings of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516583669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516583669?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:39","pubTimestamp":1741037947,"startTime":"0","endTime":"0","summary":"Acres Commercial Realty Corp  expected to post earnings of27cents a share - Earnings Preview Acres Commercial Realty Corp ACR.N, ACR is expected to show a fall in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM243:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR"],"gpt_icon":0},{"id":"2514135859","title":"Press Release: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514135859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514135859?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690900,"startTime":"0","endTime":"0","summary":"-- Announced rosnilimab, a PD-1 depleter and agonist, achieved positive. results from Phase 2b rheumatoid arthritis  trial and highest-ever. -- Full clinical and translational data for rosnilimab in RA in Q2 2025. -- Top-line Phase 2 data for rosnilimab in ulcerative colitis , moved up. -- Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122. antagonist, and Phase 1a trial to initiate this quarter for ANB101, our. -- Announced exclusive global license agreement with Vanda Pharmaceuticals. to develop and commercialize imsidolimab, an IL-36R antagonist. -- Year-end 2024 cash and investments of $420 million and reiterating cash. SAN DIEGO, Feb. 27, 2025  -- AnaptysBio, Inc. , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.once-monthly doses, achieved positive results in 424-patient Phase 2b RA. trial and hi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TEP","BK4107","L","RA","LU0053666078.USD","BK4110","ACR","ANAB","BK4139","BK4585"],"gpt_icon":0},{"id":"2514399018","title":"MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514399018","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514399018?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"Initiated the Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa  and the Phase 3 IZAR program in patients with active psoriatic arthritis  following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indications. Initiated three new trials in the beginning of 2025 with the Nanobody sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa , Phase 2 LEDA trial in palmoplantar pustulosis  and Phase 2 S-OLARIS trial in axial spondyloarthritis . Signed a three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions to tap into Komodo’s technology and real-world data. Year-end cash, cash equivalents and short-term marketable debt securities of $448.0 million expected to support a roadmap rich in potential catalysts whilst providing a cash runway to at least the end of 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moonlake-immunotherapeutics-reports-full-2024-120000479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4214","MLTX","ACR","MDA","LU1169590202.USD","BK4139","BK4110","AS","AN","BK4202","LU1169589451.USD"],"gpt_icon":0},{"id":"2512432816","title":"ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2512432816","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512432816?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:15","pubTimestamp":1739999700,"startTime":"0","endTime":"0","summary":"UNIONDALE, N.Y., Feb. 19, 2025 /PRNewswire/ --ACRES Commercial Realty Corp.   announced today that it will release its results for the fourth quarter 2024, on Wednesday, March 5, 2025, after the market closes. The Company invites investors and other interested parties to listen to its live conference call via telephone or webcast on Thursday, March 6, 2025, at 10:00 a.m. Eastern Time.The conference call can be accessed by dialing 1-800-274-8461  or 1-203-518-9814 , Conference ID ACRES or fromthe investor relations section of the Company's website at www.acresreit.com.For those unable to listen to the live conference call, a replay will be available on the Company's website and telephonically through March 20, 2025 by dialing 1-844-512-2921  or 1-412-317-6671 , passcode 11157750.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-report-211500035.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-report-211500035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","ACR"],"gpt_icon":0},{"id":"2510335228","title":"ACRES Commercial Realty Corp. (NYSE:ACR) is a favorite amongst institutional investors who own 51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510335228","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510335228?lang=en_us&edition=fundamental","pubTime":"2025-02-11 23:25","pubTimestamp":1739287511,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies ACRES Commercial Realty's stock price is sensitive to their trading actions. A total of 16 investors have a majority stake in the company with 50% ownership. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. To get a sense of who is truly in control of ACRES Commercial Realty Corp. , it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 51% ownership. That is, the group stands to benefit the most if the stock rises .Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Check out our latest analysis for ACRES Commercial Realty. While studying institutional ownersh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acres-commercial-realty-corp-nyse-152511407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACR","BK4110","NYSE"],"gpt_icon":0},{"id":"2509275558","title":"Acrivon Therapeutics announces FDA granted BDD for ACR-368","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275558","media":"TipRanks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275558?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:16","pubTimestamp":1738847797,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics  announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment. The designation reflects the FDA’s determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Clinical data presented at ESMO 2024 demonstrates statistically significant segregation of patient responders in biomarker-positive versus biomarker-negative subgroups based on prospective OncoSignature patient selection.Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  Your Smart Portfolio. Acrivo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acrivon-therapeutics-announces-fda-granted-131637686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","ACR","BK4110","ACRV","BDD"],"gpt_icon":0},{"id":"2509233509","title":"Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2509233509","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509233509?lang=en_us&edition=fundamental","pubTime":"2025-02-05 23:43","pubTimestamp":1738770196,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics  said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation.The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review for approvals.Shares of Acrivon Therapeutics were up nearly 21% in recent Wednesay trading.Price: 7.15, Change: +1.24, Percent Change: +20.98","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRV","ACR","BK4110","BK4139","LENZ"],"gpt_icon":0},{"id":"2509285305","title":"Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285305","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285305?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021122/0/en/Acrivon-Therapeutics-Announces-FDA-has-Granted-Breakthrough-Device-Designation-for-ACR-368-OncoSignature-Assay-for-Endometrial-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4110","ACR","BK4139","LENZ"],"gpt_icon":0},{"id":"2503309062","title":"Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309062?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008443/0/en/Cabaletta-Bio-Outlines-Strategic-Priorities-and-Anticipated-Key-Milestones-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","BK4139","CABA","LU1989772923.USD","ACR","LU0912757837.SGD","LU0158827781.USD","LU1363072403.SGD","LU1989772840.SGD","BK4006","LU2357305700.SGD","IE00BKVL7J92.USD","LU2111349929.HKD","LU0098860793.USD","BK4588","LU0106831901.USD","BK4504","LU2028103732.USD","LU2347655156.SGD","LU1732799900.SGD","IE0031619046.USD","CDMO","LU2023251221.USD","LU0971096721.USD","BK4581","CRS","IE00B66KJ199.SGD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU1732800096.USD","LU1074936037.SGD","LU2065731478.USD","LU1720051017.SGD","BK4585","LU0795875169.SGD","BK4127","BK4516","LU0314104364.USD","LU1668664300.SGD","IE00B7SZL793.SGD","LU2089283258.USD","LU0158827948.USD","LU0267386448.USD","LU0320765646.SGD","LU1720051108.HKD","BK4534","LU0106261372.USD","LU2089284900.SGD","LU0225283273.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2501725862","title":"MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2501725862","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501725862?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:00","pubTimestamp":1736337600,"startTime":"0","endTime":"0","summary":"New trials in three new indications have been initiated with the Nanobody sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/08/3006081/0/en/MoonLake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-the-Nanobody-sonelokimab.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4202","AS","ACR","MDA"],"gpt_icon":0},{"id":"2493093768","title":"XBiotech Pauses Rheumatology program","url":"https://stock-news.laohu8.com/highlight/detail?id=2493093768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493093768?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962400,"startTime":"0","endTime":"0","summary":"Findings from recently completed Rheumatoid Arthritis Study raise questionsAUSTIN, Texas, Dec.  23, 2024  (GLOBE NEWSWIRE) -- XBiotech(NASDAQ: XBIT) announced today data that it is halting its clinica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/23/3001269/35550/en/XBiotech-Pauses-Rheumatology-program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","ACR","BK4139","MTX","BK4110","XBIT"],"gpt_icon":0},{"id":"2493752704","title":"Protalix BioTherapeutics Issues 2025 Letter to Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2493752704","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493752704?lang=en_us&edition=fundamental","pubTime":"2024-12-23 19:50","pubTimestamp":1734954600,"startTime":"0","endTime":"0","summary":"CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.As we conclude 2024, I am filled with a sense of accomplishment as well as excitement for the year ahead. This past year, Protalix has achieved significant milestones that position our company for long-term growth. The success we have achieved this year is a direct result of our team's hard work and dedication. We're proud to share these accomplishments with you.Finally, by employing financial discipline over the last few years, we were able to repay in full all of our outstanding convertible notes, making us a debt-free company. We are proud of this achievement, and our strong balance sh","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/niBtR_lMgMpjETfrnXqPYg--~B/aD0xMjE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/protalix-biotherapeutics-issues-2025-letter-115000300.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/protalix-biotherapeutics-issues-2025-letter-115000300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999002224.SGD","SG9999003800.SGD","LU1894683348.USD","SG9999002232.USD","LU0058720904.USD","SG9999001176.SGD","IE0002270589.USD","LU0868494617.USD","IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","IE00B19Z3B42.SGD","BK4588","LU0170899867.USD","BK4007","LU1066053197.SGD","LU0225284248.USD","LU1023059063.AUD","LU1057294990.SGD","IE000M9KFDE8.USD","BK4585","BK4581","BK4534","SG9999013999.USD","LU0234572021.USD","BK4599","LU0456855351.SGD","PLX","BK4139","LU0321505439.SGD","LU0985481810.HKD","IE00BBT3K403.USD","BK4592","IE00BLSP4452.SGD","BK4110","BK4533","LU0122379950.USD","LU1066051498.USD","LU0306806265.USD","LU1894683264.USD","PFE","ACR","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0306807586.USD","LU0225771236.USD","SGXZ57979304.SGD","LU1883839398.USD"],"gpt_icon":1},{"id":"2493207830","title":"Acrux Ltd Raises A$1.34 Mln From Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2493207830","media":"T-Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493207830?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:13","pubTimestamp":1734916417,"startTime":"0","endTime":"0","summary":"Acrux Ltd :Raises A$1.34 Million From Share Purchase Plan.Further Company Coverage: Acr.Ax. ((Reuters.Briefs@Thomsonreuters.Com;)).","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ACR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACR\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":null,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"market":"US","date":"2025-03-05","symbol":"ACR","fiscalQuarterEnding":"2024/12","expectedEps":0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741150800000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-10-30","symbol":"ACR","fiscalQuarterEnding":"2024/09","expectedEps":0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730260800000,"reportTimeType":"post","actualEps":0.14},{"date":"2024-07-31","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/06","expectedEps":0.28,"defaultRemindTime":1722456000000,"name":null,"time":"Post Market","dateTimestamp":1722398400000,"actualEps":null},{"date":"2024-05-01","symbol":"ACR","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":0.35,"defaultRemindTime":1714593600000,"name":null,"time":"Post Market","dateTimestamp":1714536000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACR\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-28","value":0.16,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-28","value":0.64,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-28","value":0.42,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-28","value":0.42,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-28","value":0.42,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1728360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACR","date":"2025-04-28","current":4.368755,"percent":0.5655,"low":-0.830359,"twenty":-0.283753,"median":3.924127,"eighty":5.92678,"high":14.204017,"avg":3.839086,"sd":3.112459,"marketCap":127860350},"quantilePoints":[{"date":"2020-05-01","current":2.391384,"twenty":2.417668,"median":4.354063,"eighty":23.644331,"marketCap":86008529},{"date":"2020-05-08","current":-0.476126,"twenty":2.408405,"median":4.354063,"eighty":23.64292,"marketCap":80316788},{"date":"2020-05-15","current":-0.385121,"twenty":2.399108,"median":4.34603,"eighty":23.635049,"marketCap":64965358},{"date":"2020-05-22","current":-0.385121,"twenty":2.391757,"median":4.34603,"eighty":23.624215,"marketCap":64965358},{"date":"2020-05-29","current":-0.375728,"twenty":2.375238,"median":4.342013,"eighty":23.616544,"marketCap":63380838},{"date":"2020-06-05","current":-0.537291,"twenty":2.268298,"median":4.337996,"eighty":23.60285,"marketCap":90634598},{"date":"2020-06-12","current":-0.572985,"twenty":2.233131,"median":4.327955,"eighty":23.60285,"marketCap":96655777},{"date":"2020-06-19","current":-0.49784,"twenty":2.128917,"median":4.313896,"eighty":23.595809,"marketCap":83979610},{"date":"2020-06-26","current":-0.482811,"twenty":1.847407,"median":4.307872,"eighty":23.582109,"marketCap":81444376},{"date":"2020-07-02","current":-0.452752,"twenty":1.820352,"median":4.29783,"eighty":23.582109,"marketCap":76373909},{"date":"2020-07-10","current":-0.447117,"twenty":1.812445,"median":4.281763,"eighty":23.567545,"marketCap":75423197},{"date":"2020-07-17","current":-0.454631,"twenty":1.79588,"median":4.247621,"eighty":23.561875,"marketCap":76690813},{"date":"2020-07-24","current":-0.450874,"twenty":1.778891,"median":4.229546,"eighty":23.561368,"marketCap":76057005},{"date":"2020-07-31","current":-0.418937,"twenty":1.77303,"median":4.197413,"eighty":23.561368,"marketCap":70669634},{"date":"2020-08-07","current":-0.389478,"twenty":1.767642,"median":4.169297,"eighty":23.561368,"marketCap":82171619},{"date":"2020-08-14","current":-0.373121,"twenty":1.763277,"median":4.142325,"eighty":23.555746,"marketCap":78720623},{"date":"2020-08-21","current":-0.356571,"twenty":1.753473,"median":4.14118,"eighty":23.545397,"marketCap":75228983},{"date":"2020-08-28","current":-0.353562,"twenty":1.748369,"median":4.135155,"eighty":23.541135,"marketCap":74594139},{"date":"2020-09-04","current":-0.330994,"twenty":1.739311,"median":4.12913,"eighty":23.540628,"marketCap":69832811},{"date":"2020-09-11","current":-0.321967,"twenty":1.735731,"median":4.11708,"eighty":23.528183,"marketCap":67928280},{"date":"2020-09-18","current":-0.315949,"twenty":1.729507,"median":4.088963,"eighty":23.515678,"marketCap":66658592},{"date":"2020-09-25","current":-0.303913,"twenty":1.724061,"median":4.08093,"eighty":23.512872,"marketCap":64119217},{"date":"2020-10-02","current":-0.335508,"twenty":1.721155,"median":4.062855,"eighty":23.505565,"marketCap":70785077},{"date":"2020-10-09","current":-0.349048,"twenty":1.709118,"median":4.024697,"eighty":23.499765,"marketCap":73641873},{"date":"2020-10-16","current":-0.314444,"twenty":1.6899,"median":3.49084,"eighty":23.48763,"marketCap":66341170},{"date":"2020-10-23","current":-0.303913,"twenty":1.680487,"median":2.92946,"eighty":23.479024,"marketCap":64119217},{"date":"2020-10-30","current":-0.28285,"twenty":1.671636,"median":2.901471,"eighty":23.474204,"marketCap":59675311},{"date":"2020-11-06","current":-0.317044,"twenty":1.669001,"median":2.893012,"eighty":23.46316,"marketCap":68283910},{"date":"2020-11-13","current":-0.410817,"twenty":1.660341,"median":2.891803,"eighty":23.457665,"marketCap":88480560},{"date":"2020-11-20","current":-0.482264,"twenty":1.638881,"median":2.890595,"eighty":23.453467,"marketCap":103868483},{"date":"2020-11-27","current":-0.55371,"twenty":1.628025,"median":2.888178,"eighty":23.445171,"marketCap":119256407},{"date":"2020-12-04","current":-0.614737,"twenty":1.126039,"median":2.87972,"eighty":23.434129,"marketCap":132400258},{"date":"2020-12-11","current":-0.584968,"twenty":-0.285558,"median":2.864009,"eighty":23.429934,"marketCap":125988623},{"date":"2020-12-18","current":-0.580502,"twenty":-0.300302,"median":2.849508,"eighty":23.424434,"marketCap":125026878},{"date":"2020-12-24","current":-0.601341,"twenty":-0.300904,"median":2.831381,"eighty":23.416184,"marketCap":129515022},{"date":"2020-12-31","current":-0.593899,"twenty":-0.303913,"median":2.820506,"eighty":23.416184,"marketCap":127912114},{"date":"2021-01-08","current":-0.640041,"twenty":-0.314444,"median":2.798754,"eighty":23.409199,"marketCap":137850148},{"date":"2021-01-15","current":-0.596876,"twenty":-0.317044,"median":2.779419,"eighty":23.409199,"marketCap":128553277},{"date":"2021-01-22","current":-0.626645,"twenty":-0.321601,"median":2.768543,"eighty":23.407301,"marketCap":134964912},{"date":"2021-01-29","current":-0.59241,"twenty":-0.325277,"median":2.721413,"eighty":23.39772,"marketCap":127591532},{"date":"2021-02-05","current":-0.59241,"twenty":-0.327985,"median":2.702078,"eighty":23.395443,"marketCap":127591532},{"date":"2021-02-12","current":-0.601341,"twenty":-0.329791,"median":2.692411,"eighty":23.395443,"marketCap":129515022},{"date":"2021-02-19","current":-0.538901,"twenty":-0.336712,"median":2.68516,"eighty":23.382999,"marketCap":116066912},{"date":"2021-02-26","current":-0.585684,"twenty":-0.343632,"median":2.668242,"eighty":23.374703,"marketCap":126142837},{"date":"2021-03-05","current":-0.656758,"twenty":-0.34965,"median":2.65374,"eighty":23.37052,"marketCap":141450494},{"date":"2021-03-12","current":-0.765058,"twenty":-0.355066,"median":2.642864,"eighty":23.367731,"marketCap":151261945},{"date":"2021-03-19","current":-0.773314,"twenty":-0.359667,"median":2.636822,"eighty":23.366463,"marketCap":152894262},{"date":"2021-03-26","current":-0.730698,"twenty":-0.372029,"median":2.628363,"eighty":23.358624,"marketCap":144468510},{"date":"2021-04-01","current":-0.728783,"twenty":-0.374023,"median":2.619904,"eighty":23.353962,"marketCap":144089825},{"date":"2021-04-09","current":-0.733571,"twenty":-0.377896,"median":2.605403,"eighty":23.351176,"marketCap":145036538},{"date":"2021-04-16","current":-0.733507,"twenty":-0.38625,"median":2.600569,"eighty":23.341486,"marketCap":145023804},{"date":"2021-04-23","current":-0.728759,"twenty":-0.394383,"median":2.571519,"eighty":23.333221,"marketCap":144085138},{"date":"2021-04-30","current":-0.716127,"twenty":-0.403156,"median":2.562972,"eighty":23.333221,"marketCap":141587548},{"date":"2021-05-07","current":12.280556,"twenty":-0.403908,"median":2.564193,"eighty":23.325539,"marketCap":145696522},{"date":"2021-05-14","current":11.159187,"twenty":-0.403156,"median":2.571519,"eighty":23.313402,"marketCap":132392591},{"date":"2021-05-21","current":12.000214,"twenty":-0.401278,"median":2.600569,"eighty":23.309699,"marketCap":142370539},{"date":"2021-05-28","current":12.008001,"twenty":-0.399569,"median":2.605403,"eighty":23.297233,"marketCap":142462928},{"date":"2021-06-04","current":12.880178,"twenty":-0.397861,"median":2.619904,"eighty":23.282034,"marketCap":152810430},{"date":"2021-06-11","current":13.61997,"twenty":-0.394449,"median":2.629572,"eighty":23.269611,"marketCap":161587329},{"date":"2021-06-18","current":13.253968,"twenty":-0.393243,"median":2.638031,"eighty":23.261298,"marketCap":157245073},{"date":"2021-06-25","current":13.191669,"twenty":-0.389358,"median":2.644073,"eighty":23.248872,"marketCap":156505966},{"date":"2021-07-02","current":12.545324,"twenty":-0.388504,"median":2.655244,"eighty":23.240563,"marketCap":148837728},{"date":"2021-07-09","current":12.958051,"twenty":-0.387002,"median":2.668242,"eighty":23.229518,"marketCap":153734314},{"date":"2021-07-16","current":12.630985,"twenty":-0.385121,"median":2.68516,"eighty":23.229518,"marketCap":149854001},{"date":"2021-07-23","current":12.919114,"twenty":-0.385121,"median":2.696036,"eighty":23.229518,"marketCap":153272372},{"date":"2021-07-30","current":13.627758,"twenty":-0.378951,"median":2.704495,"eighty":23.222589,"marketCap":161679717},{"date":"2021-08-06","current":2.692645,"twenty":-0.378071,"median":2.712954,"eighty":23.210305,"marketCap":158604894},{"date":"2021-08-13","current":2.590862,"twenty":-0.377634,"median":2.699661,"eighty":23.201855,"marketCap":152609520},{"date":"2021-08-20","current":2.612452,"twenty":-0.375728,"median":2.692528,"eighty":23.188037,"marketCap":153881266},{"date":"2021-08-27","current":2.524548,"twenty":-0.374625,"median":2.68516,"eighty":23.18112,"marketCap":148703443},{"date":"2021-09-03","current":2.529174,"twenty":-0.374625,"median":2.668242,"eighty":23.18112,"marketCap":148975960},{"date":"2021-09-10","current":2.444355,"twenty":-0.373422,"median":2.655244,"eighty":23.164533,"marketCap":143979815},{"date":"2021-09-17","current":2.424306,"twenty":-0.373121,"median":2.644073,"eighty":23.160386,"marketCap":142798908},{"date":"2021-09-24","current":2.478282,"twenty":-0.372318,"median":2.638031,"eighty":23.160386,"marketCap":145978273},{"date":"2021-10-01","current":2.530717,"twenty":-0.372,"median":2.630356,"eighty":23.160386,"marketCap":149066799},{"date":"2021-10-08","current":2.432017,"twenty":-0.36928,"median":2.624738,"eighty":23.127211,"marketCap":143253103},{"date":"2021-10-15","current":2.422764,"twenty":-0.367258,"median":2.617487,"eighty":23.118917,"marketCap":142708069},{"date":"2021-10-22","current":2.422764,"twenty":-0.362252,"median":2.608928,"eighty":23.109059,"marketCap":142708069},{"date":"2021-10-29","current":2.421222,"twenty":-0.359194,"median":2.602389,"eighty":23.099865,"marketCap":142617230},{"date":"2021-11-05","current":2.948349,"twenty":-0.357001,"median":2.601479,"eighty":23.065008,"marketCap":135081545},{"date":"2021-11-12","current":2.972158,"twenty":-0.356571,"median":2.605403,"eighty":23.045624,"marketCap":136172379},{"date":"2021-11-19","current":2.906683,"twenty":-0.355367,"median":2.614969,"eighty":23.037354,"marketCap":133172587},{"date":"2021-11-26","current":2.84716,"twenty":-0.355066,"median":2.621242,"eighty":23.035979,"marketCap":130445503},{"date":"2021-12-03","current":2.698354,"twenty":-0.354164,"median":2.629572,"eighty":23.023539,"marketCap":123627794},{"date":"2021-12-10","current":2.672561,"twenty":-0.353562,"median":2.636203,"eighty":23.015245,"marketCap":122446058},{"date":"2021-12-17","current":2.432487,"twenty":-0.351757,"median":2.629572,"eighty":23.015245,"marketCap":111446820},{"date":"2021-12-23","current":2.45828,"twenty":-0.349951,"median":2.622321,"eighty":23.001399,"marketCap":112628556},{"date":"2021-12-31","current":2.474153,"twenty":-0.348446,"median":2.614969,"eighty":22.97803,"marketCap":113355779},{"date":"2022-01-07","current":2.45828,"twenty":-0.34634,"median":2.605403,"eighty":22.973988,"marketCap":112628556},{"date":"2022-01-14","current":2.628911,"twenty":-0.344535,"median":2.605403,"eighty":22.973776,"marketCap":120446196},{"date":"2022-01-21","current":2.41463,"twenty":-0.344234,"median":2.601479,"eighty":22.969629,"marketCap":110628695},{"date":"2022-01-28","current":2.329315,"twenty":-0.342428,"median":2.593946,"eighty":22.948894,"marketCap":106719875},{"date":"2022-02-04","current":2.416614,"twenty":-0.33972,"median":2.588548,"eighty":22.928309,"marketCap":110719598},{"date":"2022-02-11","current":2.402726,"twenty":-0.338517,"median":2.584693,"eighty":22.90988,"marketCap":110083278},{"date":"2022-02-18","current":2.333283,"twenty":-0.337915,"median":2.570395,"eighty":22.898273,"marketCap":106901681},{"date":"2022-02-25","current":2.245983,"twenty":-0.335508,"median":2.564193,"eighty":22.890838,"marketCap":102901958},{"date":"2022-03-04","current":3.243244,"twenty":-0.330994,"median":2.564193,"eighty":22.871107,"marketCap":110020560},{"date":"2022-03-11","current":3.039484,"twenty":-0.330994,"median":2.570395,"eighty":22.849369,"marketCap":103108427},{"date":"2022-03-18","current":3.155514,"twenty":-0.32949,"median":2.584693,"eighty":22.828635,"marketCap":107044517},{"date":"2022-03-25","current":3.422888,"twenty":-0.32949,"median":2.588548,"eighty":22.828635,"marketCap":116114636},{"date":"2022-04-01","current":3.397664,"twenty":-0.328951,"median":2.593946,"eighty":22.827656,"marketCap":115258964},{"date":"2022-04-08","current":3.274067,"twenty":-0.327985,"median":2.601479,"eighty":22.8079,"marketCap":111066173},{"date":"2022-04-14","current":3.248843,"twenty":-0.327985,"median":2.605403,"eighty":22.791313,"marketCap":110210502},{"date":"2022-04-22","current":3.127915,"twenty":-0.327985,"median":2.612452,"eighty":22.72819,"marketCap":106108277},{"date":"2022-04-29","current":2.868089,"twenty":-0.326782,"median":2.621242,"eighty":22.688706,"marketCap":97294170},{"date":"2022-05-06","current":4.375842,"twenty":-0.326481,"median":2.628911,"eighty":22.657479,"marketCap":100429958},{"date":"2022-05-13","current":4.21343,"twenty":-0.325277,"median":2.630625,"eighty":22.634624,"marketCap":96702425},{"date":"2022-05-20","current":3.735933,"twenty":-0.322569,"median":2.636822,"eighty":22.60654,"marketCap":85743401},{"date":"2022-05-27","current":3.743573,"twenty":-0.321967,"median":2.642864,"eighty":22.591302,"marketCap":85918746},{"date":"2022-06-03","current":3.785593,"twenty":-0.321967,"median":2.651324,"eighty":22.545587,"marketCap":86883140},{"date":"2022-06-10","current":3.678634,"twenty":-0.321692,"median":2.668242,"eighty":22.48538,"marketCap":84428318},{"date":"2022-06-17","current":3.224057,"twenty":-0.320881,"median":2.67161,"eighty":22.421163,"marketCap":73995328},{"date":"2022-06-24","current":3.193497,"twenty":-0.319259,"median":2.686797,"eighty":22.367371,"marketCap":73293950},{"date":"2022-07-01","current":3.304276,"twenty":-0.317289,"median":2.691936,"eighty":22.325763,"marketCap":75836444},{"date":"2022-07-08","current":3.227877,"twenty":-0.316825,"median":2.692645,"eighty":22.317329,"marketCap":74083000},{"date":"2022-07-15","current":2.998678,"twenty":-0.315949,"median":2.699661,"eighty":22.30517,"marketCap":68822669},{"date":"2022-07-22","current":3.055978,"twenty":-0.315949,"median":2.704495,"eighty":22.284437,"marketCap":70137752},{"date":"2022-07-29","current":3.174397,"twenty":-0.315648,"median":2.716828,"eighty":22.263703,"marketCap":72855589},{"date":"2022-08-05","current":5.232925,"twenty":-0.314444,"median":2.726247,"eighty":22.238823,"marketCap":77625212},{"date":"2022-08-12","current":5.466621,"twenty":-0.314444,"median":2.760853,"eighty":22.205649,"marketCap":81091851},{"date":"2022-08-19","current":5.438471,"twenty":-0.312338,"median":2.772168,"eighty":22.201502,"marketCap":80674282},{"date":"2022-08-26","current":5.815674,"twenty":-0.303913,"median":2.785945,"eighty":22.182759,"marketCap":86269703},{"date":"2022-09-02","current":5.460991,"twenty":-0.303612,"median":2.798754,"eighty":22.174132,"marketCap":81008337},{"date":"2022-09-09","current":5.427211,"twenty":-0.302408,"median":2.815672,"eighty":22.174132,"marketCap":80507255},{"date":"2022-09-16","current":5.179496,"twenty":-0.300904,"median":2.822922,"eighty":22.164182,"marketCap":76832650},{"date":"2022-09-23","current":4.898002,"twenty":-0.300904,"median":2.831036,"eighty":22.164182,"marketCap":72656962},{"date":"2022-09-30","current":4.588358,"twenty":-0.300904,"median":2.842292,"eighty":22.164182,"marketCap":68063706},{"date":"2022-10-07","current":4.802294,"twenty":-0.300904,"median":2.861593,"eighty":22.122715,"marketCap":71237228},{"date":"2022-10-14","current":4.644657,"twenty":-0.300904,"median":2.866049,"eighty":22.122715,"marketCap":68898843},{"date":"2022-10-21","current":4.802294,"twenty":-0.299399,"median":2.878511,"eighty":22.101982,"marketCap":71237228},{"date":"2022-10-28","current":5.731225,"twenty":-0.297895,"median":2.885762,"eighty":22.101982,"marketCap":85016997},{"date":"2022-11-04","current":5.658037,"twenty":-0.294886,"median":2.890595,"eighty":22.081248,"marketCap":83931318},{"date":"2022-11-11","current":3.269547,"twenty":-0.287363,"median":2.891803,"eighty":22.060514,"marketCap":82896095},{"date":"2022-11-18","current":3.224437,"twenty":-0.28285,"median":2.893012,"eighty":22.039781,"marketCap":81752380},{"date":"2022-11-25","current":3.264743,"twenty":-0.281646,"median":2.900263,"eighty":22.039781,"marketCap":82774284},{"date":"2022-12-02","current":3.208315,"twenty":-0.278938,"median":2.909515,"eighty":22.039781,"marketCap":81343618},{"date":"2022-12-09","current":3.027746,"twenty":0.690334,"median":2.920572,"eighty":22.023194,"marketCap":76765484},{"date":"2022-12-16","current":2.937462,"twenty":1.319576,"median":2.928984,"eighty":21.985873,"marketCap":74476418},{"date":"2022-12-23","current":2.498939,"twenty":1.458571,"median":2.923052,"eighty":21.878059,"marketCap":63358094},{"date":"2022-12-30","current":2.663385,"twenty":1.56152,"median":2.918116,"eighty":21.803418,"marketCap":67527465},{"date":"2023-01-06","current":2.889096,"twenty":1.56152,"median":2.920572,"eighty":21.803418,"marketCap":73250132},{"date":"2023-01-13","current":3.121255,"twenty":1.56152,"median":2.934238,"eighty":21.803418,"marketCap":79136303},{"date":"2023-01-20","current":3.163173,"twenty":1.56152,"median":2.940687,"eighty":21.803418,"marketCap":80199084},{"date":"2023-01-27","current":3.03742,"twenty":1.56152,"median":2.963813,"eighty":21.803418,"marketCap":77010741},{"date":"2023-02-03","current":3.089011,"twenty":1.56152,"median":2.97938,"eighty":21.803418,"marketCap":78318780},{"date":"2023-02-10","current":2.995502,"twenty":1.56152,"median":2.986046,"eighty":21.803418,"marketCap":75947961},{"date":"2023-02-17","current":3.069664,"twenty":1.56152,"median":2.995967,"eighty":21.803418,"marketCap":77828265},{"date":"2023-02-24","current":3.101909,"twenty":1.56152,"median":3.006318,"eighty":21.803418,"marketCap":78645789},{"date":"2023-03-03","current":7.166438,"twenty":1.56152,"median":3.021298,"eighty":21.803418,"marketCap":76129066},{"date":"2023-03-10","current":6.673589,"twenty":1.565877,"median":3.03742,"eighty":21.803418,"marketCap":70893541},{"date":"2023-03-17","current":6.627828,"twenty":1.596379,"median":3.047969,"eighty":21.803418,"marketCap":70407414},{"date":"2023-03-24","current":7.581198,"twenty":1.601086,"median":3.061417,"eighty":21.803418,"marketCap":80535062},{"date":"2023-03-31","current":7.413404,"twenty":1.645072,"median":3.077506,"eighty":21.786831,"marketCap":78752596},{"date":"2023-04-06","current":7.192223,"twenty":1.601086,"median":3.08741,"eighty":21.803418,"marketCap":76402982},{"date":"2023-04-14","current":7.390524,"twenty":1.5571,"median":3.105133,"eighty":21.820005,"marketCap":78509533},{"date":"2023-04-21","current":7.375972,"twenty":1.513114,"median":3.121255,"eighty":21.836592,"marketCap":78354950},{"date":"2023-04-28","current":6.610326,"twenty":1.469128,"median":3.128557,"eighty":21.853179,"marketCap":70221497},{"date":"2023-05-05","current":6.094842,"twenty":1.469128,"median":3.146532,"eighty":21.853179,"marketCap":64745508},{"date":"2023-05-12","current":6.315875,"twenty":1.469128,"median":3.161027,"eighty":21.853179,"marketCap":69335675},{"date":"2023-05-19","current":6.24252,"twenty":1.469128,"median":3.171711,"eighty":21.853179,"marketCap":68530383},{"date":"2023-05-26","current":5.892774,"twenty":1.469128,"median":3.174891,"eighty":21.853179,"marketCap":64690871},{"date":"2023-06-02","current":6.111565,"twenty":1.469128,"median":3.178756,"eighty":21.853179,"marketCap":67092760},{"date":"2023-06-09","current":6.149999,"twenty":1.469128,"median":3.189323,"eighty":21.853179,"marketCap":67514692},{"date":"2023-06-16","current":6.082393,"twenty":1.469128,"median":3.199227,"eighty":21.853179,"marketCap":66772508},{"date":"2023-06-23","current":6.049574,"twenty":1.458571,"median":3.208315,"eighty":21.878059,"marketCap":66412225},{"date":"2023-06-30","current":6.257426,"twenty":1.448015,"median":3.216397,"eighty":21.902939,"marketCap":68694019},{"date":"2023-07-07","current":6.250133,"twenty":1.448015,"median":3.224292,"eighty":21.902939,"marketCap":68613956},{"date":"2023-07-14","current":6.578319,"twenty":1.448015,"median":3.243521,"eighty":21.902939,"marketCap":72216789},{"date":"2023-07-21","current":6.702301,"twenty":1.448015,"median":3.24834,"eighty":21.902939,"marketCap":73577860},{"date":"2023-07-28","current":6.578319,"twenty":1.448015,"median":3.264991,"eighty":21.902939,"marketCap":72216789},{"date":"2023-08-04","current":6.184495,"twenty":1.448015,"median":3.286333,"eighty":21.902939,"marketCap":67893390},{"date":"2023-08-11","current":6.351685,"twenty":1.448015,"median":3.322273,"eighty":21.902939,"marketCap":70535467},{"date":"2023-08-18","current":6.122833,"twenty":1.448015,"median":3.390097,"eighty":21.902939,"marketCap":67994059},{"date":"2023-08-25","current":6.050115,"twenty":1.448015,"median":3.429194,"eighty":21.902939,"marketCap":67186529},{"date":"2023-09-01","current":6.166463,"twenty":1.448015,"median":3.730203,"eighty":21.902939,"marketCap":68478577},{"date":"2023-09-08","current":5.810147,"twenty":1.448015,"median":3.743573,"eighty":21.902939,"marketCap":64521678},{"date":"2023-09-15","current":6.006485,"twenty":1.448015,"median":3.764583,"eighty":21.902939,"marketCap":66702011},{"date":"2023-09-22","current":5.868321,"twenty":1.448015,"median":4.024697,"eighty":21.902939,"marketCap":65167703},{"date":"2023-09-29","current":5.991941,"twenty":1.448015,"median":4.078921,"eighty":21.902939,"marketCap":66540504},{"date":"2023-10-06","current":5.970126,"twenty":1.448015,"median":4.113063,"eighty":21.902939,"marketCap":66298245},{"date":"2023-10-13","current":5.82469,"twenty":1.448015,"median":4.135155,"eighty":21.902939,"marketCap":64683185},{"date":"2023-10-20","current":5.263018,"twenty":1.448015,"median":4.142325,"eighty":21.902939,"marketCap":58445820},{"date":"2023-10-27","current":5.453103,"twenty":1.416345,"median":4.14118,"eighty":21.97758,"marketCap":60556704},{"date":"2023-11-03","current":5.639187,"twenty":1.416345,"median":4.14118,"eighty":14.071633,"marketCap":62623174},{"date":"2023-11-10","current":4.597236,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60968545},{"date":"2023-11-17","current":4.691483,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":62218453},{"date":"2023-11-24","current":4.594442,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60931496},{"date":"2023-12-01","current":4.552014,"twenty":1.416345,"median":4.14118,"eighty":13.99376,"marketCap":60368804},{"date":"2023-12-08","current":5.091467,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":67523030},{"date":"2023-12-15","current":5.430898,"twenty":1.426902,"median":4.14118,"eighty":13.959496,"marketCap":72024565},{"date":"2023-12-22","current":6.121882,"twenty":1.426902,"median":4.144334,"eighty":13.959496,"marketCap":81188405},{"date":"2023-12-29","current":5.921861,"twenty":1.416345,"median":4.173313,"eighty":13.99376,"marketCap":78535715},{"date":"2024-01-05","current":5.994596,"twenty":1.319576,"median":4.201799,"eighty":14.009335,"marketCap":79500329},{"date":"2024-01-12","current":6.030963,"twenty":1.319576,"median":4.247621,"eighty":14.009335,"marketCap":79982637},{"date":"2024-01-19","current":5.897615,"twenty":1.222807,"median":4.282189,"eighty":14.024909,"marketCap":78214176},{"date":"2024-01-26","current":5.909738,"twenty":1.319576,"median":4.311888,"eighty":14.009335,"marketCap":78374946},{"date":"2024-02-02","current":6.079454,"twenty":1.319576,"median":4.327955,"eighty":14.009335,"marketCap":80625713},{"date":"2024-02-09","current":5.976412,"twenty":1.319576,"median":4.350046,"eighty":14.009335,"marketCap":79259176},{"date":"2024-02-16","current":6.085515,"twenty":1.319576,"median":4.362096,"eighty":14.009335,"marketCap":80706098},{"date":"2024-02-23","current":6.321904,"twenty":1.319576,"median":4.386196,"eighty":14.009335,"marketCap":83841096},{"date":"2024-03-01","current":6.697703,"twenty":1.416345,"median":4.576259,"eighty":13.99376,"marketCap":88824938},{"date":"2024-03-08","current":3.802021,"twenty":1.416345,"median":4.594442,"eighty":13.99376,"marketCap":85127249},{"date":"2024-03-15","current":3.670771,"twenty":1.416345,"median":4.552014,"eighty":13.627758,"marketCap":82188558},{"date":"2024-03-22","current":4.518879,"twenty":1.416345,"median":4.374799,"eighty":13.542097,"marketCap":101177708},{"date":"2024-03-28","current":4.473036,"twenty":1.416345,"median":4.324209,"eighty":13.253968,"marketCap":100151267},{"date":"2024-04-05","current":4.548166,"twenty":1.319576,"median":4.316791,"eighty":13.048383,"marketCap":101833436},{"date":"2024-04-12","current":4.421557,"twenty":1.319576,"median":4.316791,"eighty":12.951821,"marketCap":98998672},{"date":"2024-04-19","current":4.434543,"twenty":1.319576,"median":4.316791,"eighty":12.824109,"marketCap":99289417},{"date":"2024-04-26","current":4.434543,"twenty":1.416345,"median":4.324209,"eighty":12.732219,"marketCap":99289417},{"date":"2024-05-03","current":4.212125,"twenty":1.416345,"median":4.309328,"eighty":12.514175,"marketCap":94309475},{"date":"2024-05-10","current":3.932803,"twenty":1.416345,"median":4.212125,"eighty":12.280556,"marketCap":98662220},{"date":"2024-05-17","current":3.918344,"twenty":1.416345,"median":4.14347,"eighty":12.078087,"marketCap":98299491},{"date":"2024-05-24","current":3.756405,"twenty":1.416345,"median":3.988402,"eighty":12.000214,"marketCap":94236929},{"date":"2024-05-31","current":3.606033,"twenty":1.416345,"median":3.918344,"eighty":11.314932,"marketCap":90464550},{"date":"2024-06-07","current":3.788005,"twenty":1.416345,"median":3.860508,"eighty":9.717873,"marketCap":95029691},{"date":"2024-06-14","current":3.851139,"twenty":1.319576,"median":3.804358,"eighty":7.887548,"marketCap":96613519},{"date":"2024-06-21","current":3.893228,"twenty":1.222807,"median":3.802673,"eighty":7.521707,"marketCap":97669405},{"date":"2024-06-28","current":3.839113,"twenty":0.932501,"median":3.800901,"eighty":7.413404,"marketCap":96311838},{"date":"2024-07-05","current":3.953355,"twenty":0.932501,"median":3.800901,"eighty":7.375972,"marketCap":99177812},{"date":"2024-07-12","current":4.109685,"twenty":0.932501,"median":3.800901,"eighty":7.207477,"marketCap":103099673},{"date":"2024-07-15","current":4.193863,"twenty":0.932501,"median":3.800901,"eighty":7.194036,"marketCap":105211444},{"date":"2024-08-02","current":4.458422,"twenty":-0.282248,"median":3.785593,"eighty":6.893892,"marketCap":111848438},{"date":"2024-08-09","current":4.330188,"twenty":-0.282248,"median":3.785593,"eighty":6.71397,"marketCap":112034952},{"date":"2024-08-16","current":4.293515,"twenty":-0.282248,"median":3.785593,"eighty":6.684421,"marketCap":111086122},{"date":"2024-08-23","current":4.437385,"twenty":-0.282248,"median":3.785593,"eighty":6.626684,"marketCap":114808456},{"date":"2024-08-30","current":4.443027,"twenty":-0.282248,"median":3.785593,"eighty":6.593741,"marketCap":114954430},{"date":"2024-09-06","current":4.420459,"twenty":-0.282248,"median":3.785593,"eighty":6.572485,"marketCap":114370534},{"date":"2024-09-13","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.489344,"marketCap":112764822},{"date":"2024-09-20","current":4.358398,"twenty":-0.282248,"median":3.785593,"eighty":6.439122,"marketCap":112764822},{"date":"2024-09-27","current":4.403533,"twenty":-0.282248,"median":3.785593,"eighty":6.403286,"marketCap":113932613},{"date":"2024-10-04","current":4.45149,"twenty":-0.282248,"median":3.785593,"eighty":6.389947,"marketCap":115173391},{"date":"2024-10-11","current":4.474057,"twenty":-0.282248,"median":3.785593,"eighty":6.366105,"marketCap":115757286},{"date":"2024-10-18","current":4.327367,"twenty":-0.282248,"median":3.785593,"eighty":6.321904,"marketCap":111961965},{"date":"2024-10-25","current":4.321725,"twenty":-0.282248,"median":3.785593,"eighty":6.261802,"marketCap":111815992},{"date":"2024-10-31","current":4.27941,"twenty":-0.282248,"median":3.785593,"eighty":6.240491,"marketCap":110721187},{"date":"2024-11-08","current":4.441959,"twenty":-0.282549,"median":3.784012,"eighty":6.202291,"marketCap":116779104},{"date":"2024-11-15","current":4.397133,"twenty":-0.282549,"median":3.784012,"eighty":6.149605,"marketCap":115600635},{"date":"2024-11-22","current":4.560596,"twenty":-0.282549,"median":3.784012,"eighty":6.139391,"marketCap":119898057},{"date":"2024-11-29","current":4.732231,"twenty":-0.282549,"median":3.784012,"eighty":6.120618,"marketCap":124410349},{"date":"2024-12-06","current":4.80034,"twenty":-0.282549,"median":3.784012,"eighty":6.102487,"marketCap":126200941},{"date":"2024-12-13","current":4.66957,"twenty":-0.282549,"median":3.784012,"eighty":6.088852,"marketCap":122763004},{"date":"2024-12-20","current":4.171011,"twenty":-0.282549,"median":3.784012,"eighty":6.078382,"marketCap":109655869},{"date":"2024-12-27","current":4.405306,"twenty":-0.282549,"median":3.784012,"eighty":6.067331,"marketCap":115815506},{"date":"2025-01-03","current":4.489762,"twenty":-0.282549,"median":3.784012,"eighty":6.059453,"marketCap":118035841},{"date":"2025-01-10","current":4.745853,"twenty":-0.28285,"median":3.782431,"eighty":6.049147,"marketCap":124768467},{"date":"2025-01-17","current":4.822135,"twenty":-0.28285,"median":3.782431,"eighty":6.037025,"marketCap":126773931},{"date":"2025-01-24","current":4.890244,"twenty":-0.28285,"median":3.782431,"eighty":6.035572,"marketCap":128564523},{"date":"2025-01-31","current":4.794891,"twenty":-0.28285,"median":3.782431,"eighty":6.016756,"marketCap":126057694},{"date":"2025-02-07","current":5.012841,"twenty":-0.28285,"median":3.782431,"eighty":6.002169,"marketCap":131787589},{"date":"2025-02-14","current":5.165406,"twenty":-0.28285,"median":3.782431,"eighty":5.999213,"marketCap":135798516},{"date":"2025-02-21","current":5.375182,"twenty":-0.28285,"median":3.782431,"eighty":5.991941,"marketCap":141313540},{"date":"2025-02-28","current":5.6231,"twenty":-0.28285,"median":3.782431,"eighty":5.970126,"marketCap":147831296},{"date":"2025-03-07","current":5.080493,"twenty":-0.283753,"median":3.782268,"eighty":5.951081,"marketCap":148690780},{"date":"2025-03-14","current":5.481842,"twenty":-0.283753,"median":3.782268,"eighty":5.922788,"marketCap":160437065},{"date":"2025-03-21","current":11.366901,"twenty":-0.283753,"median":3.788005,"eighty":5.926495,"marketCap":332675095},{"date":"2025-03-28","current":5.041233,"twenty":-0.283753,"median":3.800901,"eighty":5.92678,"marketCap":147541761},{"date":"2025-04-04","current":4.869586,"twenty":-0.283753,"median":3.829511,"eighty":5.92678,"marketCap":142518184},{"date":"2025-04-11","current":4.150082,"twenty":-0.28285,"median":3.860508,"eighty":5.926495,"marketCap":121460451},{"date":"2025-04-17","current":4.12892,"twenty":-0.28285,"median":3.878196,"eighty":5.926495,"marketCap":120841106},{"date":"2025-04-25","current":4.180649,"twenty":-0.283753,"median":3.918344,"eighty":5.92678,"marketCap":122355061},{"date":"2025-04-28","current":4.368755,"twenty":-0.283753,"median":3.924127,"eighty":5.92678,"marketCap":127860350}],"updateTime":1745965496352}}}